Breaking News, Collaborations & Alliances

GSK, Hengrui Sign $500M Drug Development Pact

Aim to develop up to 12 innovative medicines across respiratory, immunology & inflammation, and oncology.

Author Image

By: Charlie Sternberg

Associate Editor

GSK plc has entered into agreements with China-based biotechnology company Hengrui Pharma to develop up to 12 innovative medicines. The programs, which GSK will pay $500 million for, complement GSK’s Respiratory, Immunology & Inflammation (RI&I) and Oncology pipeline. HRS-9821 Plus Eleven Other Programs The agreements include an exclusive worldwide license (excluding mainland China, Hong Kong, Macau and Taiwan) for a potential best-in-class, PDE3/4 inhibitor (HRS-9821) in clinical ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters